SCHEMBL15064402

SCHEMBL15064402

Cn1nc(-c2ccc(O)cc2)c2ncc(F)cc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51
ESR1 P03372 2/20 0.38
LIMK1 P53667 1/20 0.35
NAMPT P43490 4/20 0.35
ESR2 Q92731 2/20 0.35
NR3C1 P04150 1/20 0.35
EGFR P00533 2/20 0.34
MAP4K4 O95819 1/20 0.34
FRK P42685 1/20 0.34
MAPK9 P45984 1/20 0.34
CSNK1A1 P48729 1/20 0.34
PIK3CD O00329 2/20 0.34
PIK3CA P42336 2/20 0.34
MTOR P42345 2/20 0.34
CSNK1D P48730 1/20 0.34
CSNK1E P49674 1/20 0.34
PIK3CG P48736 2/20 0.33
MAPK14 Q16539 1/20 0.33
BRAF P15056 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL570560 0.82 ESR1 (0.42) KDM4EALDH1A1ESR1
SCHEMBL15065064 0.82 PRKDC (0.44) KDM4EALDH1A1ESR1EGFRPIK3CD
SCHEMBL570307 0.79 TGFBR1 (0.37) KDM4EALDH1A1ESR1ESR2NR3C1
SCHEMBL15064423 0.75 NAMPT (0.53) KDM4EALDH1A1ESR1NAMPT
SCHEMBL4030264 0.74 NAMPT (0.53) KDM4EALDH1A1ESR1NAMPTESR2
SCHEMBL569696 0.70 ALDH1A1 (0.40) KDM4EALDH1A1
SCHEMBL12987576 0.70 GABRG2 (0.44) ESR1ESR2PIK3CDPIK3CAMTOR
SCHEMBL33526226 0.68 KDM4E (0.35) KDM4EALDH1A1
SCHEMBL31632812 0.68 ALDH1A1 (0.50) KDM4EALDH1A1
SCHEMBL4031900 0.68 ESR1 (0.43) ESR1NAMPTESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2601192-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICALS CO (JP) 2017-03-01 EP disclosed
US-9029536-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-12 US disclosed
US-20130172292-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172292-A1 FUSED HETEROCYCLIC COMPOUNDS PDE10A, PDE3A, PDE2A KDM4E 1619/4885ALDH1A1 270/4885ESR1 1158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.